Racial/ethnic differences in prevalence of hallucinogen use by age cohort: Findings from the 2018 National Survey on Drug Use and Health
Zoe W. Jahn, Joel A Lopez, Sara de la Salle, Sonya C. Faber, Monnica T. Williams
Journal of Psychedelic Studies July 15, 2021 DOI: 10.1556/2054.2021.00166 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 56,313 |
| Population | Non-institutionalized U.S. population age 12 and older |
| Keywords | Ethnic group Demography Population Epidemiology Cohort study Gerontology |
| Citations | 36 |
| Key findings | Lifetime and past-year hallucinogen use varied significantly by race/ethnicity and age cohort, with non-Hispanic White and multi-racial individuals reporting the highest rates and Black/African Americans the lowest. |
Abstract
Abstract Background Few studies have assessed the epidemiology of hallucinogenic substance use among racial and ethnic groups of varying age cohorts. Use of psychedelic substances may differ among people of color (POC), due to factors such as stigma and discriminatory drug enforcement practices against POC. The lack of inclusion of POC in psychedelic research further underscores the importance of identifying differences in use among racial/ethnic groups and age cohorts.
Methods: Data from the 2018 National Survey on Drug Use and Health (NSDUH) was used for this analysis ( N = 56,313, unweighted), representative of the non-institutionalized U.S. population. Proportions of lifetime hallucinogen use by race/ethnicity were compared. Proportions of past year rates of use were compared to examine differences by race/ethnicity and age cohort.
Results: Approximately 15.9% of the U.S. population over 12 had used a hallucinogen at some point in their lifetime and 2.0% had used in the past year. Lifetime hallucinogen use was most prevalent among non-Hispanic White and multi-racial individuals, while Black/African Americans reported the lowest rates of use. White and multi-racial groups also reported the highest proportions of past year use among 12–34 year olds, and White individuals reported the highest proportions among 35–49 year olds. Hispanic individuals reported higher proportions of use among the 12–17 cohort, but lower proportions among the 26–49 year old cohorts. Black/African Americans reported the lowest rates of past year use among the 12–25 year old cohorts. 50+ and older cohorts reported the lowest rates of hallucinogen use in the past year.
Limitations: Data is cross-sectional and self-reported. “Race” is a social construction is subject to change over time, and NSDUH ethnoracial categories are limited. Institutionalized populations are not included in the study.
Conclusions: Significant differences in hallucinogen use among ethnoracial groups by substance and age cohorts were observed. Findings from this work may inform education, interventions, and therapeutic psychedelic research.
Citations in the library
Cited by 24
- The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision Frontiers in Psychiatry January 20, 2022
- Psychedelics and Racial Justice International Journal of Mental Health and Addiction April 1, 2024
- Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? Psychedelic Medicine June 1, 2024
- Acid liberalism: Silicon Valley's enlightened technocrats, and the legalization of psychedelics. International Journal of Drug Policy December 1, 2022
- Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019 Frontiers in Epidemiology March 23, 2022
and 19 more in the library
Cites 22
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
and 17 more in the library